3b Blackbio Dx Limited (3BBLACKBIO)

Loading page…

3b Blackbio Dx Limited (3BBLACKBIO) · mywealthgrid

About

3b Blackbio Dx Limited is a healthcare services provider with ₹1,010 Cr market capitalisation and zero debt. Current metrics (PE 6.2x, OPM 51.95%, ROE 19.41%) suggest strong performance. However, quarterly data through Mar 2021 documents significant volatility—revenue ₹2.4–5.9 Cr and OPM 1–7% with losses in three quarters—creating a gap that makes recent metrics difficult to verify independently.

Face value: ₹10

Market cap

₹1,416 Cr

P/E

8.7×

P/B

5.3×

Dividend yield

0.3%

ROE

19.4%

ROCE

25.3%

Debt / equity

OPM

52%

EPS (TTM)

₹190.0

Book value

₹313.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Historical volatility and missing recent data: quarterly revenue ₹2.39–5.87 Cr with OPM 1–7% and losses in three of eight quarters (through Mar 2021); lack of recent quarterly disclosure makes it difficult to verify whether current 51.95% OPM and 19.41% ROE are sustainable.
Stock underperformance: 1-year return of −21.69% despite PE 6.2, zero debt, and strong metrics; verify what August 2026 results revealed and whether market concerns reflect structural or temporary issues.
Limited institutional ownership (FII 2.5%, DII 2.15%, public 54.4%); verify analyst coverage and research depth available.
Small historical scale (~₹10–24 Cr annualised through 2021); verify current revenue run-rate and whether operations have stabilised at a higher base.

Generated analysis · source review pending

Growth drivers

Consistent dividend payments 2021–2025 and zero debt (D/E 0) demonstrate cash generation and financial flexibility for reinvestment or acquisitions in the fragmented healthcare services sector.
ROE 19.41% indicates efficient capital deployment at current scale; verify whether revenue can expand without proportional capex to drive earnings growth.
OPM of 51.95% represents significant improvement from historical 1–7% range through Mar 2021; verify what drove the expansion and whether it reflects sustainable operational gains or composition changes.
Small historical revenue base (~₹10–24 Cr annualised through 2021) provides room for organic growth if business stabilises; verify recent revenue trajectory and current run-rate.

Generated analysis · source review pending

2,206 historical price candles were omitted because the exchange source has not been verified.

₹1,646.8+1.5%1Y

Quick read

rule-based

Pros

+Strong return on equity of 45.4% (3-yr avg)
+High return on capital employed of 21.6%
+Healthy operating margin of 52%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 582.8×

Cons

−Profit declined 28.5% a year over the last 3 years
−Modest revenue growth of 6.2% a year over the last 3 years
−Low dividend payout of 2.6% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

56/100

Business quality: 85
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB	₹33,605 Cr	₹33,605 Cr	₹2,891 Cr	₹838 Cr	28.3%	₹542 Cr	18.5%	28.8%	21.6%	-79
Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA	₹14,694 Cr	₹14,694 Cr	₹857 Cr	₹362 Cr	41.4%	₹187 Cr	21.3%	21.3%	19.7%	-117
Metropolis Healthcare LimitedMETROPOLISMETROPOLIS	₹11,151 Cr	₹11,169 Cr	₹1,710 Cr	₹422 Cr	24.4%	₹202 Cr	11.6%	17.3%	13.4%	-57
Thyrocare Technologies LimitedTHYROCARETHYROCARE	₹8,495 Cr	₹8,495 Cr	₹876 Cr	₹282 Cr	31.6%	₹176 Cr	19.6%	36.5%	28.8%	4
Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS	₹6,509 Cr	₹6,589 Cr	₹999 Cr	₹227 Cr	22.7%	₹77 Cr	7.7%	17.1%	9.1%	-61
Suraksha Diagnostic LimitedSURAKSHASURAKSHA	₹1,824 Cr	₹1,826 Cr	₹325 Cr	₹102 Cr	30.7%	₹36 Cr	10.1%	16.8%	14.1%	-101
Krsnaa Diagnostics LimitedKRSNAAKRSNAA	₹1,798 Cr	₹2,332 Cr	₹815 Cr	₹218 Cr	27.4%	₹97 Cr	13.1%	13.1%	10.9%	65
3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO	₹1,416 Cr	₹1,417 Cr	₹96 Cr	₹50 Cr	52%	₹163 Cr	49.4%	25.3%	19.4%	235
One Global Service Provider LtdONEGLOBALONEGLOBAL	₹1,025 Cr	₹1,025 Cr	₹6 Cr	₹1 Cr	22.2%	₹1 Cr	17.3%	17.6%	19.5%	—
Health X Platform LimitedHEALTHXHEALTHX	₹868 Cr	₹890 Cr	₹1,468 Cr	₹-67 Cr	-4%	₹-20 Cr	-0.1%	—	0.2%	—
Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF	₹797 Cr	₹820 Cr	₹104 Cr	₹38 Cr	36.1%	₹24 Cr	23.4%	23.1%	16.1%	92
Aspira Pathlab & Diagnostics LtdASPIRAASPIRA	₹135 Cr	₹136 Cr	₹22 Cr	₹4 Cr	16%	₹2 Cr	9.2%	17.5%	18.1%	16

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	227	81	62	74	96
COGS	52	32	18	22	26
Gross profit	175	49	44	52	71
	25	12	15	19	21
Operating profit (EBITDA)	150	37	29	33	50
OPM %	66.2%	46%	47.1%	44.5%	52%
Depreciation	1	1	1	1	1
Interest	0	0	0	0	0
	3	7	7	13	15
Profit before tax	152	43	35	44	64
Tax	38	11	9	12	16
Tax %	25.1%	25.5%	26.5%	27.6%	25.5%
	114	32	26	32	48
PAT margin %	50.2%	39.9%	42%	43.3%	49.4%
EPS (₹)	152	43.4	34.6	39.9	55.7
EPS adjusted (₹)	22.3	174.4	217.4	37.5	55.7
	5.9%	5.8%	7.2%	7.5%	7.2%
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	7	7	7	7	9	9
Reserves	—	125	146	164	214	260
Minority interest	—	16	19	25	2	3
	—	2	3	2	1	0
	6	43	17	16	22	24
Total equity & liabilities	13	194	192	214	248	296
	4	5	7	8	7	7
CWIP	—	0	0	0	0	0
Investments	—	59	93	92	117	156
	9	130	93	114	123	132
Total assets	13	194	192	214	248	296

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	98	37	23	27	43
	-70	-28	12	-20	-34
	-2	-15	-5	-4	-3
Net cash flow	26	-6	30	3	6
Free cash flow	—	—	—	—	—
CFO / Operating profit %	65%	100.6%	78.6%	81.7%	86.5%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	77.3%	60.8%	71%	70.5%	73.4%
EBITDA margin %	66.2%	46%	47.1%	44.5%	52%
EBIT margin %	65.9%	45.2%	45.7%	43.1%	50.8%
PAT margin %	50.2%	39.9%	42%	43.3%	49.4%
Working capital
Receivable days	56	136	200	179	138
Inventory days	34	86	164	141	124
Payable days	21	41	69	66	28
NWC days	70	181	295	253	235
Leverage
Current ratio	2.76	4.82	8.06	7.04	7.11
Debt to EBITDA	0.01	0.07	0.07	0.03	0.01
Debt to equity	0.02	0.02	0.01	0	0
Interest coverage	662	393.9	177.5	370.4	582.8
Asset turnover	1.17	0.42	0.29	0.3	0.33
Return ratios
Return on assets %	58.8%	16.8%	12.1%	12.9%	16.1%
Return on capital employed %	101.1%	26.6%	18.9%	20.7%	25.3%
Return on equity %	86.2%	21%	15.2%	14.4%	17.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	38.43%	38.43%	41.29%	41.29%	41.29%	41.29%	41.28%	41.28%	41.28%	41.28%	40.94%	40.95%
	3.16%	3.38%	2.97%	3.28%	3.27%	2.68%	2.49%	2.7%	2.64%	2.57%	2.57%	2.5%
	0.82%	1.18%	1.89%	1.96%	1.96%	1.74%	1.6%	1.76%	1.82%	1.88%	1.98%	2.15%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	57.59%	57.01%	53.85%	53.47%	53.48%	54.29%	54.63%	54.26%	54.26%	54.27%	54.51%	54.4%
No. of shareholders	—	—	—	—	—	—	—	—	10,709	10,507	10,616	11,049

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	137	0.02	0.04%	0.002%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Jun 2026Transcript AI Summary PPT REC
Feb 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

22 announcementsExport CSV

30 Sept 2026, 5:01 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Sept 2026, 4:42 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

29 Sept 2026, 3:26 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

18 Sept 2026, 5:45 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

16 Sept 2026, 12:27 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

11 Sept 2026, 2:16 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

11 Sept 2026, 12:34 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

8 Sept 2026, 3:31 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
30 Sept 2026, 5:01 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
30 Sept 2026, 4:42 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Loading announcements…

3b Blackbio Dx Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

13

1

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

3b Blackbio Dx Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Dividends13

Board meetings1

Board and management

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

13

1